Patents for C12Q 1 - Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions (300,231)
02/2005
02/24/2005WO2005017181A2 System for detecting polynucleotides
02/24/2005WO2005017180A2 Immobilization of oligonucleotides and proteins in sugar-containing hydrogels
02/24/2005WO2005017173A1 Methods and compositions for amplification of dna
02/24/2005WO2005017153A2 Methods for synthesis of defined polynucleotides
02/24/2005WO2005017150A1 Compositions and methods for prognosis and therapy of liver cancer
02/24/2005WO2005017146A1 Interaction inhibitors, method of detecting interaction inhibitor and kit for detecting interaction inhibitor
02/24/2005WO2005017143A1 Diagnosis and treatment of neurodegenerative disorders, involving the microtubule associated protein tau (mapt) gene
02/24/2005WO2005017141A1 Improved halohydrin dehalogenases and related polynucleotides
02/24/2005WO2005017138A2 Active-site titration of glycosyl hydrolases
02/24/2005WO2005017136A1 Methods and compositions for determination of glycated proteins
02/24/2005WO2005017133A1 Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics
02/24/2005WO2005017129A1 Phosphoramide and uses thereof
02/24/2005WO2005017128A2 Improved reagents for recombinogenic engineering and uses thereof
02/24/2005WO2005017125A2 Method for isolation and replication of infectious human hepatitis-c virus
02/24/2005WO2005017119A2 Ups as modifiers of the beta catenin pathway and methods of use
02/24/2005WO2005017118A2 Sulfs as modifiers of the beta catenin pathway and methods of use
02/24/2005WO2005017113A2 Metalloproteinase gene polymorphism in copd
02/24/2005WO2005017110A2 Engineered proteases for affinity purification and processing of fusion proteins
02/24/2005WO2005017109A2 Nucleic acids and polypeptides required for cell survival in the absence of rb
02/24/2005WO2005017106A2 Libraries of optimized cytochrome p450 enzymes and the optimized p450 enzymes
02/24/2005WO2005017104A2 Cancer-linked gene as target for chemotherapy
02/24/2005WO2005017103A2 Bacterial nitric oxide synthases and uses thereof
02/24/2005WO2005017102A2 Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
02/24/2005WO2005017025A2 Study of polymer molecules and conformations with a nanopore
02/24/2005WO2005016971A1 Organic material-immobiling structure and method for production of the same, and peptide and dna therefor
02/24/2005WO2005016966A2 Intron fusion proteins, and methods of identifying and using same
02/24/2005WO2005016954A2 Immunologic activity measure(s) for t “helper” on-associated conditions
02/24/2005WO2005016527A2 Non-pressure based fluid transfer in assay detection systems and related methods
02/24/2005WO2005016387A2 Dna-dependent mri contrast agents
02/24/2005WO2005016375A1 C1-inh as a drug for treating viruses pathogenic to humans
02/24/2005WO2005016342A1 Sir2 regulation
02/24/2005WO2005016287A2 Prkwnks as modifiers of the rac pathway and methods of use
02/24/2005WO2005016282A2 Prkcs as modifiers of the beta catenin pathway and methods of use
02/24/2005WO2005016279A2 Melks as modifiers of the rac pathway and methods of use
02/24/2005WO2005016257A2 Process of making flowable hemostatic compositions and devices containing such compositions
02/24/2005WO2005016256A2 Hemostatic compositions containing sterile thrombin
02/24/2005WO2005016246A2 Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases
02/24/2005WO2005016227A2 Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof
02/24/2005WO2005016126A2 Multifactorial assay for cancer detection
02/24/2005WO2005008252A3 Methods and compositions for assaying homocysteine
02/24/2005WO2005003392A3 Hmg coenzyme a reductase inhibitors affect the mitochondrial dna content of cells
02/24/2005WO2004108950A3 Methods for incorporating non-perfectly matched oligonucleotides into target-specific hybridization sequences
02/24/2005WO2004104587A3 Methods of identifying modulators of human retrovirus replication
02/24/2005WO2004101811A3 Detection result storing method
02/24/2005WO2004101762A3 Detection and treatment of cancers of the colon
02/24/2005WO2004092400A3 Medium for the detection and identification of micro-organisms
02/24/2005WO2004090145A3 Compounds and methods to enhance raav transduction
02/24/2005WO2004084818A3 Measurement of estrogen activity in plants and a composition therefrom
02/24/2005WO2004072224A3 Detection of ochratoxin a producing fungi
02/24/2005WO2004070053A3 cDNA AMPLIFICATION FOR EXPRESSION PROFILING
02/24/2005WO2004061082A3 Fanc gene mutations in cancer
02/24/2005WO2004055196A3 Method for identifying risk of breast cancer and treatments thereof
02/24/2005WO2004052293A3 Recombinant vaccine against flavivirus infection
02/24/2005WO2004048523A3 Modulation of ku86 expression
02/24/2005WO2004044136A3 Compositions comprising alternating 2’-modified nucleosides for use in gene modulation
02/24/2005WO2004042365A3 Development of therapeutics for the treatment of endotoxin-mediated diseases
02/24/2005WO2004042352A3 Substrates of n-end rule ubiquitylation and methods for measuring the ubiquitylation of these substrates
02/24/2005WO2004042029A3 Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
02/24/2005WO2004038045A3 Method for diagnosing diffuse-type gastric cancer
02/24/2005WO2004036177A3 Assays to detect or quantify bacterial or viral pathogens and contaminants
02/24/2005WO2004036171A3 Disease detection by digital protein truncation assays
02/24/2005WO2004031725A3 Ratios of collagen peptides, their uses and products
02/24/2005WO2004031413A3 Method for diagnosing non-small cell lung cancers
02/24/2005WO2004031409A3 Method for diagnosing chronic myeloid leukemia
02/24/2005WO2004029301A3 Method for assaying replication of hbv and testing susceptibility to drugs
02/24/2005WO2004029216A3 Diagnosis of invasive mold infection
02/24/2005WO2004021871A3 Hcv assay
02/24/2005WO2004017816A3 Methods for diagnosing dementia-related neurological disorders
02/24/2005WO2004016220A3 Apicomplexan pathways, inhibitiors, and drug delivery
02/24/2005WO2004015062A3 Methods and compositions relating to gene silencing
02/24/2005WO2004011594A8 Novel method for analyzing nucleic acid and use thereof for evaluating the degree of mrna editing of the serotonin 5-ht2c receptor
02/24/2005WO2003102206A3 Sgk and nedd used as diagnostic and therapeutic targets
02/24/2005WO2003097791A3 Polynucleotide sequences encoding alkaline a-galactosidases and methods of using same
02/24/2005WO2003093503A3 Method for bioequivalence determination using expression profiling
02/24/2005WO2003053921A3 Mutant proteinase inhibitors and uses thereof
02/24/2005US20050044582 Novel polynucleotides and uses therefor
02/24/2005US20050044406 Adaptive behavioral intrusion detection systems and methods
02/24/2005US20050043894 Integrated biosensor and simulation system for diagnosis and therapy
02/24/2005US20050043528 Enterococcus faecalis polynucleotides and polypeptides
02/24/2005US20050043513 Nucleotide sequences coding olfactory receptor protein for use in pest control, cosmetics, deodorants and treatment and prevention of disorders associated with loss of smell
02/24/2005US20050043511 G-protein coupled receptor lustr2 and uses thereof
02/24/2005US20050043507 Acyl-nucleotide probes and methods of their synthesis and use in proteomic analysis
02/24/2005US20050043414 Trityl-type compounds and their use
02/24/2005US20050043319 Molecular target of neurotoxicity
02/24/2005US20050043265 High affinity RNA ligands of basic fibroblast growth factor
02/24/2005US20050043254 contacting MT 0039 protein or the transformant expressing the protein with a candidate for screening an agent capable of controlling an activity of the protein
02/24/2005US20050043219 Derivatized oligonucleotides having improved uptake and other properties
02/24/2005US20050042749 Dopaminergic neurons and proliferation-competent precursor cells for treating Parkinson's disease
02/24/2005US20050042744 Device which utilizes optical information to detect fermentative and non-fermentative microorganisms
02/24/2005US20050042738 Carbohydrate-associated proteins
02/24/2005US20050042731 Four helical bundle cytokine family polypeptide for use in treatment, diagnosis and prevention of infection, cardiovascular, metabolic, developmental, skin, bone, inflammatory and autoimmune disorders
02/24/2005US20050042730 Gene screening method using nuclear receptor
02/24/2005US20050042727 UDP-N-acetylglucosamine: galactose-Beta 1,3-N-A-acetylgalactosamine-alpha-R/N-acetylglucosamine-Beta 1,3-N-acetylgalactosamine-alpha-R (GIcNAc to GalNac) Beta 1,6-N-acetylglucosaminyltransferase, C2/4GnT
02/24/2005US20050042724 Sodium-dependent phosphate cotransporter (NAPTR) for use tool in identifying modulators for treatment and prevention of cell proliferative, nervous system and cardiovascular disorders
02/24/2005US20050042713 Characterising polypeptides
02/24/2005US20050042712 Cell-free system for monitoring efficacy of bactericidal/microbiocidal agents; in vitro drug screening
02/24/2005US20050042711 Field test for fungi
02/24/2005US20050042710 Sterility sampling test method and apparatus
02/24/2005US20050042709 Fructosyl amino acid oxidase acts on glycated hemoglobin in presence of tetrazolium compound and sodium azide
02/24/2005US20050042708 Providing cysteine mutants of an enzyme, reacting with methanethiosulfonate reagents to form disulfide side chains and testing for amidase or esterase activity; detergent additive, feed additives, textile antisoilant treatment